Surmodics (NASDAQ:SRDX - Get Free Report) will issue its quarterly earnings data before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.36) per share for the quarter. Parties interested in registering for the company's conference call can do so using this link.
Surmodics Price Performance
Shares of NASDAQ SRDX traded down $0.85 during mid-day trading on Wednesday, hitting $26.07. 62,844 shares of the stock traded hands, compared to its average volume of 58,651. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.84 and a quick ratio of 3.97. Surmodics has a twelve month low of $16.79 and a twelve month high of $39.41. The company has a market cap of $371.24 million, a PE ratio of 68.61 and a beta of 1.01. The firm has a 50 day simple moving average of $29.00 and a two-hundred day simple moving average of $31.75.
Analyst Ratings Changes
SRDX has been the topic of several recent research reports. StockNews.com downgraded Surmodics from a "strong-buy" rating to a "buy" rating in a report on Wednesday. Needham & Company LLC reaffirmed a "buy" rating and set a $47.00 target price on shares of Surmodics in a report on Wednesday, April 10th.
View Our Latest Stock Report on SRDX
About Surmodics
(
Get Free Report)
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
Recommended Stories
Before you consider Surmodics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surmodics wasn't on the list.
While Surmodics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
